NCT00216021 - Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions

Metastatic Breast Cancer

Interventions

DRUG

Capecitabine

Capecitabine 825 mg/m2 po bid, days 1-14

DRUG

Oxaliplatin

Oxaliplatin 100 mg/m2 IV, day 1

Trial Locations (11)

Helen F. Graham Cancer Center, Newark

Indiana University Cancer Center, Indianapolis

Quality Cancer Center (MCGOP), Indianapolis

Community Regional Cancer Center, Indianapolis

Elkhart Clinic, Elkhart

Northern Indiana Cancer Research Consortium, South Bend

Center for Cancer Care, Inc., P.C., New Albany

Medical Consultants, P.C., Muncie

Oncology Hematology Associates of SW Indiana, Evansville

AP&S Clinic, Terre Haute

Medical & Surgical Specialists, LLC, Galesburg